This has been further suggested by various reports which show enhanced ICI efficacy when combined with myeloid-focused therapies including combinations of GM-CSF activated DCs loaded with tumor-antigen [44, 68] stimulator of interferon genes (STING) vaccine strategies [69], and indolamine 2,3 dioxygenase inhibitors [29, 70]. The gene discussed is IDO1; the disease is neoplasm.